Almirall stock holds steady as investors focus on latest annual figures
Published on 09/03/2026 at 22:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Almirall stock, tied to the Spanish pharmaceutical group Almirall S.A. (ISIN ES0157097017), is trading today in a relatively steady pattern as investors look at the company’s most recently available full-year figures and await fresh interim data as of September 3, 2026.
Annual report frames Almirall’s recent performance
According to the published 2025 Annual Accounts and Management Report, Almirall’s latest available full-year data gives investors the most concrete reference point for the company’s revenue and profitability trends up to the end of fiscal year 2025.
These annual disclosures, which cover the company’s performance for fiscal year 2025 with a period end within the last 24 months relative to September 3, 2026, now serve primarily as historical context rather than current trading drivers. Historical: the 2025 report details Almirall’s revenue, earnings, and cash flow profile for that fiscal year, forming the baseline against which upcoming interim figures for 2026 will be compared.
Market view and stock portal data
For short-term traders, the focus on Almirall stock is supported by its listing details and sector classification. A German stock portal overview for Almirall (ISIN ES0157097017) on boerse.de confirms the association of the ISIN with the Almirall share and places the company clearly in the pharma sector.
As of September 3, 2026, stock-quote information for Almirall’s American depositary receipts traded in the United States shows a price reference in the mid-teens in USD for the ADR, with a previous close of 14.07 USD and an indicated open of 15.80 USD on the same quote snapshot. Historical comparison: this places the ADR price regionally in line with prior months’ trading ranges around the low- to mid-teens per share and shows that the current level is neither at an extreme high nor at a pronounced low relative to those historical levels.
Almirall stock and background information
Investors can find more news and historical data on Almirall stock as well as regulatory and sector information via the thematic overview linked here.
Dermatology portfolio with approved acne treatment
Almirall’s business profile is anchored in dermatology, with a portfolio that includes treatments for acne, psoriasis, and other skin conditions. A notable product example is sarecycline, marketed under the brand name Seysara for non-nodular moderate-to-severe acne vulgaris in patients nine years and older.
According to a report in Dermatology Times referencing a company release, the United States Food and Drug Administration approved sarecycline for this indication in October in an earlier period, underscoring Almirall’s positioning in prescription dermatology and its focus on targeted oral antibiotics for acne. While this approval predates September 3, 2026 and therefore functions as historical information, it still illustrates the type of specialty products underpinning Almirall’s revenue base.
Stock perspective for retail investors
From a stock perspective, Almirall shares represent exposure to a European pharmaceutical group with a clear dermatology focus. As of the latest available quote context around September 3, 2026, the ADR price near 14.07 USD, with an indicated open of 15.80 USD on the same snapshot, shows that the share is trading in the mid-teens range in USD, with historical movements that have kept the stock broadly within this band rather than at extreme highs or lows.
Almirall stock facts
- Company: Almirall S.A.
- ISIN: ES0157097017
- Ticker: ALMRY
- Trading venue: ADR on a US exchange
- Price (as of September 3, 2026): 14.07 USD
- Market capitalization: based on ADR price in the mid-teens range (as of September 3, 2026)
- Sector / Industry: Pharmaceuticals / Dermatology
- Index membership: not part of major global headline indices
